LB Pharmaceuticals (LBRX) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.79

Estimate

-$1.60

Surprise

-12.1%

Score today

5.3/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

LB Pharmaceuticals (LBRX) reported a wider loss than forecast — adjusted EPS of -$1.79 against the -$1.60 estimate (a 12.1% shortfall).

• LB Pharmaceuticals Reports Financial Results for the Third Quarter Ended September 30, 2026 — fiscal.ai, 2026-11-05
• LB Pharmaceuticals On Track For Phase 3 NOVA-2 LB-102 Schizophrenia Topline Data In 1H27; Cash $403.8M Funds Operations — benzinga, 2026-11-05
• LB Pharmaceuticals Q3 GAAP EPS $(1.79) vs $(0.61) YoY — benzinga, 2026-11-05

TrendMatrix currently rates LBRX Sell at 5.3/10; no pre/post engine snapshot brackets this report.

0 of the last 4 quarters beat the estimate; this quarter's -12.1% surprise compares with a -57.4% four-quarter average. Next scheduled report: 2027-03-25.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$42.01

Price target

$50.46

Stop

$39.07

Upside to target

+20.1%

Reward-to-risk

1.3:1

Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.36B

P/E (fwd)

-7.8

52-week range

$14.32–$50.16

Off 52-week high

16.2%

RSI (14)

60

Volume vs avg

1.21×

Score today

5.3/10